美國Seracare陽性對照品

廣州健侖生物科技有限公司

廣州健侖長期供應各種生物原料，主要代理品牌：美國Seracare、西班牙Certest、美國Fuller等等。

主要產品包括各種標準品、陽性對照品、陽性質控品、單克隆抗原抗體。

其中常見的有：弓形蟲病、西尼羅河病毒、類風濕因子、瘧疾、麻疹、萊姆病、百日咳桿菌、大腸桿菌、鼠傷寒沙門氏菌、李斯特菌等陽性對照品。

美國Seracare陽性對照品

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

歡迎咨詢

歡迎咨詢2042552662

【Seracare產品介紹】

美國Seracare陽性對照品

在培養皿中，誘導胚胎干細胞形成視網膜的過程，扼要地再現了胚胎中眼睛發育的主要步驟。這項技術對基礎研究的價值不可估量，同時有助于開發一些療法，幫助視力減退的患者恢復視力。如下圖所示，在加入名為生長因子的分子之后，胚胎干細胞開始聚集;大約5天后，開始形成zui原始的視泡。及至第7天，視泡向外凸出;幾天后，該結構內陷，形成視杯;到第24天，視網膜的所有層次初具雛形。
應用前景
聽說我們的研究后，人們自然想知道，用小鼠胚胎干細胞所做的工作究竟能否給眼疾患者帶來好處。在這個方向上，我們已取得了一些進展。值得一提的是，我的實驗室zui近剛剛在一篇文章中報道過，我們成功地使人類胚胎干細胞分化成視杯和多層神經組織。我們預計，同樣的培養方法也可應用于人類的誘導多能干細胞(induced pluripotent stem cells，iPS)——成熟細胞受到特定刺激后，經過逆轉的發育過程，可成為誘導多能干細胞，其行為與胚胎干細胞相似。我們還發明了更好的低溫貯存方法，能在液氮中儲存由人類胚胎細胞分化成的視網膜組織。
這些工作都將推動體外培養的視網膜組織應用于醫學。例如，我們可以制造人工視網膜，幫助人們研究常見眼部疾病的病理機制，推動新藥和基因療法的研究，逆轉視網膜病變。
*有數百萬人患有黃斑變性、視網膜色素變性(retinitis pigmentosa)和青光眼(glaucoma)，這三種視網膜退行性疾病的患者也許都可以從我們的研究中獲益。三種疾病中，發生病變的視網膜細胞層各不相同。在黃斑變性中，由于支撐組織“崩潰”，視網膜上皮的完整性受到影響，光感受器細胞也發生退化，尤其是視網膜中心區域。在視網膜色素變性中，視桿細胞(rod，光感受器細胞的一種)數量一年年逐漸減少，zui初也是zui常見的癥狀是“夜盲”，而后來，患者會喪失大部分視野，只剩下一小塊中心視野。在青光眼病例中，受損的則是神經節細胞，這類細胞會伸出視神經，把視網膜與大腦后部皮層上的視覺處理中心連接起來。
黃斑變性可能是這三種疾病中zui容易用細胞替代療法緩解的一種。使用傳統培養方法和我們的新方法，人類胚胎干細胞和誘導多能干細胞都比較容易產生支撐組織的細胞，即視網膜色素上皮細胞，并可從培養基中直接提取出來。美國已開始用這種細胞進行早期小規模臨床實驗，其他國家也有類似的實驗計劃。在這些實驗中，研究人員會用細針，將干細胞分化成的色素上皮細胞注射到色素上皮和光感受器細胞層之間，至少替代部分受損組織。

美國Seracare陽性對照品

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、食品安全、化妝品檢測、藥物濫用檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

想了解更多的產品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-103室

The process of inducing embryonic stem cells to form the retina in petri dishes briefly reproduces the major steps in eye development in the embryo. The technology is invaluable to basic research and helps to develop therapies that help patients with vision loss regain their eyesight. As shown in the figure below, embryonic stem cells began to aggregate after the addition of a molecule called growth factor; about five days later, the most primitive vesicles began to form. By day 7, the vesicles bulged outward; a few days later, the structure retracted to form an optic cup; by day 24, all layers of the retina were initially rudimentary.
Application prospects
After hearing about our research, it is natural to wonder whether the work done with mouse embryonic stem cells can benefit patients with eye diseases. In this direction, we have made some progress. It is worth mentioning that my laboratory recently reported in an article that we successfully differentiated human embryonic stem cells into optic cups and multiple layers of neural tissue. We expect that the same culture can also be applied to human induced pluripotent stem cells (iPS), which are induced pluripotent stem cells by reversing the development of specific stimuli Embryonic stem cells are similar. We have also invented better cryogenic storage methods that store retinal tissue differentiated from human embryonic cells in liquid nitrogen.
These efforts will promote the use of cultured retinal tissue in medicine. For example, we can make artificial retina to help people study the pathological mechanism of common eye diseases, promote the research of new drugs and gene therapy, and reverse the retinopathy.
Millions of people worldwide have macular degeneration, retinitis pigmentosa and glaucoma, and all three patients with retinal degenerative diseases may benefit from our study. Of the three diseases, retinal layers of the lesion vary. In macular degeneration, the integrity of the retinal epithelium is affected by the collapsing of the supporting tissue, and the photoreceptor cells also degenerate, especially in the central retinal region. In retinitis pigmentosa, the number of rods (a type of photoreceptor cells) gradually decreases year by year, the first and most common symptom is "night blindness", and later, the patient will lose most of the field of vision, leaving only A small central field of vision. In glaucoma cases, ganglion cells are damaged, and these cells extend the optic nerve, connecting the retina to the visual processing center on the posterior cortex of the brain.
Macular degeneration may be the easiest of these three diseases to be alleviated by cell replacement therapy. Both human embryonic stem cells and induced pluripotent stem cells are more likely to produce cells that support the tissues, the retinal pigment epithelial cells, which can be extracted directly from the medium using traditional culture methods and our new approach. The United States has begun to use such cells for early small-scale clinical trials, other countries have a similar experimental plan. In these experiments, researchers injected tiny pieces of fine pigment into the pigment epithelium differentiated from stem cells between the pigment epithelium and the photoreceptor cell layer, replacing at least some of the damaged tissue.